03-24-2009: The US medical agency FDA has granted Phadia the clearance to sell and market its new POC allergy test ImmunoCAP® Rapid product in US.
“This is a historical event in the diagnostic industry since it is the first semi-quantitative POC allergy test that has been FDA cleared. It is a major milestone for Phadia in building the ImmunoCAP franchise even stronger and will provide more patients with allergy-like symptoms the possibility to get a correct diagnosis” says Håkan Englund, Executive Vice President Phadia AB.
ImmunoCAP Rapid will be introduced on the US market later in the year. The European version of ImmunoCAP Rapid has been marketed and sold in selected European countries for over 2 years.
Thermo Fisher Scientific Completes Acquisition of Phadia
Thermo Fisher Scientific Inc. reported that it has completed its previously announced acquisition of Phadia. Based in Uppsala, Sweden, Phadia has approximately 1,500 employees globally and had 2010 revenue of €367 million (or approximately $525 million). Phadia will become part of Thermo Fi ... more
New POC allergy test has been cleared by FDA
The US medical agency FDA has granted Phadia the clearance to sell and market its new POC allergy test ImmunoCAP® Rapid product in US. “This is a historical event in the diagnostic industry since it is the first semi-quantitative POC allergy test that has been FDA cleared. It is a major mi ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
